Public annual accounts

PHARMA BIO CONSULT financials

Name: PHARMA BIO CONSULT financials
Creator: Upswitch
License: https://www.upswitch.app/terms-and-conditions

A multi-period view of the public annual-account figures reported for PHARMA BIO CONSULT, with comparable measures and links to available source documents.

Company overview

Registry number

0719347149

Fiscal coverage

2024–2025

Public sources

cbso_bulk

Data updated

Jul 27, 2026

Financial evidence

Latest movements for PHARMA BIO CONSULT

2025 versus 2024

Operating line: €48,990
EBITDA: €47,823
Total assets: €155,655
Equity: €34,629

EBITDA margin +97.6% · Equity ratio +22.2%

Multi-year filings

Filed annual accounts by fiscal year

Public regulator-filed figures across 2 years.

Source: NBB/CBSO

Fiscal year	Gross margin	EBITDA	Total assets	Equity	Filing
202531 Dec 2025	€48,990	€47,823	€155,655	€34,629	-
202431 Dec 2024	€63,903	€62,718	€88,412	€18,600	-

Gross margin line from gross margin (abbreviated schema). This is not reported turnover, so it is not used as a public valuation base.EBITDA basis: operating profit plus full add-backs.

Figures reproduce public filings and may use country-specific accounting definitions. They are not audited by Upswitch.

Public company datasets

Explore the underlying reports

Valuation

2 valuation checkpoints · 2024 to 2025 · Method family

Open report